Similarly the study of the impact of p53 isoforms is at an early stage of development, but it is already clear that different isoforms can radically alter transcriptional activity and core functionality, again differentially impacting cancer initiation, progression and response to treatment [32, 33]. This evidence concerns the gene TP53 and cancer.